Pacira BioSciences (PCRX) Expected to Announce Earnings on Thursday

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) is anticipated to release its Q1 2025 earnings data after the market closes on Thursday, May 8th. Analysts expect the company to announce earnings of $0.61 per share and revenue of $176.35 million for the quarter.

Pacira BioSciences Stock Performance

PCRX stock traded down $0.30 during mid-day trading on Friday, hitting $26.45. 494,366 shares of the company were exchanged, compared to its average volume of 986,693. Pacira BioSciences has a 1-year low of $11.16 and a 1-year high of $31.67. The business has a 50 day simple moving average of $24.61 and a 200-day simple moving average of $21.75. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $1.22 billion, a PE ratio of -13.03 and a beta of 0.71.

Analyst Ratings Changes

Several research analysts have weighed in on PCRX shares. Barclays lifted their target price on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and raised their price target for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Needham & Company LLC reissued a "buy" rating and set a $32.00 price target on shares of Pacira BioSciences in a research note on Tuesday, April 8th. HC Wainwright raised their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a report on Tuesday, April 8th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, Pacira BioSciences currently has an average rating of "Hold" and an average target price of $26.67.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.